Moderna targets $1.1B in R&D spending cuts, drops 5 programs …

Sep 12, 2024 · Moderna has vowed to cut R&D spending by $1.1 billion by 2027. The decision to shrink the budget by more than 20% follows commercial setbacks that have persuaded the …

20%
OFF

Moderna Targets $1.1B In R&D Spending Cuts, Drops 5 Programs …

2 weeks from now

Sep 12, 2024 · Moderna has vowed to cut R&D spending by $1.1 billion by 2027. The decision to shrink the budget by more than 20% follows commercial setbacks that have persuaded the …

fiercebiotech.com

20%
OFF

Fierce Biotech On LinkedIn: Moderna Targets $1.1B In R&D …

2 weeks from now

Moderna has vowed to cut R&D spending by $1.1 billion by 2027. The decision to shrink the budget by more than 20% follows commercial setbacks that have persuaded the biotech to …

linkedin.com

$1
OFF

Moderna To Slash Costs By $1.1B - LinkedIn

2 weeks from now

Sep 12, 2024 · Moderna's target is to lower R&D expenditures to a range between $3.6 billion and $3.8 billion by 2027, a decrease from the forecasted $4.8 billion at the end of the current year.

linkedin.com

$1
OFF

McLean Collins On LinkedIn: Moderna Targets $1.1B In R&D …

2 weeks from now

More tough news out this morning with one of the most successful biotechs in the Flagship Portfolio tightening belts. This is painful for all of the scientists and professionals impacted but …

linkedin.com

$1
OFF

Ganesh R. Manjeri, PhD On LinkedIn: Moderna Targets $1.1B In …

2 weeks from now

Ganesh R. Manjeri, PhD’s Post Ganesh R. Manjeri, PhD Principal Medical Writer at GSK 1d

linkedin.com

$11
OFF

Fierce Biotech On LinkedIn: Merck Battled 2 Other Big Pharmas To …

2 weeks from now

Merck battled 2 other Big Pharmas to the end in pursuit of $11B Prometheus deal fiercebiotech.com

linkedin.com

$76
OFF

Fierce Biotech On LinkedIn: Moderna's Gene Therapy Expansion …

2 weeks from now

Moderna is keeping its foot on the gas in 2023 when it comes to expanding beyond mRNA. ... Fierce Biotech’s Post ... this month sees the biotech giant hand over $76 million in cash and …

linkedin.com

$604
OFF

Moderna’s Cash Juggernaut Rolls On With Record $604M IPO

2 weeks from now

Dec 7, 2018 · Moderna’s IPO always looked like a record breaker for biotech and came in even larger than expected at $604 million, valuing the company at an eye-watering $7.9 billion.

fiercebiotech.com

FAQs about Moderna targets $1.1B in R&D spending cuts, drops 5 programs … Coupon?

Who is Fierce Biotech?

Fierce Biotech | 89,445 followers on LinkedIn. The dominant B2B news brand for biotech. Delivering news, revealing insights straight to your inbox. | Fierce Biotech is the dominant B2B news brand for the industry. Our focus daily is on biotech and medtech companies. ...

Will Moderna double its rare disease pipeline in 2023?

Moderna is looking to double its rare disease pipeline, with the first product launch possible by 2024. (Maddie Meyer/Getty Images) As Moderna prepares for seasonal uptake of its multi-billion-dollar COVID vaccine, the mRNA company is confident that the rest of its pipeline can make clinical and commercial in-roads in 2023. ...

Is Moderna partnering with AstraZeneca?

Moderna was responsible for discovery and preclinical development before AstraZeneca took the baton for early clinical development. Both companies were slated to split costs of late-stage studies, but as of now, none of Moderna’s pipeline-reflected programs are in partnership with AstraZeneca. ...

Will Moderna's mRNA pipeline make clinical and commercial in-roads in 2023?

As Moderna prepares for seasonal uptake of its multi-billion-dollar COVID vaccine, the mRNA company is confident that the rest of its pipeline can make clinical and commercial in-roads in 2023. And while much of Moderna’s hype has centered on treating respiratory diseases, some of the more exciting prospects are elsewhere. ...

Does Vir Biotechnology have T-cell engagers from Sanofi?

Vir Biotechnology has welcomed a trio of clinical-stage T-cell engagers from Sanofi, while eliminating a quarter of its workforce and a clutch of preclinical vaccine programs. ...